Navigation Links
Kendle Leaders Adopt 10b5-1 Trading Plans
Date:3/7/2008

CINCINNATI, March 7 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Chairman and Chief Executive Officer Candace Kendle, PharmD, and President and Chief Operating Officer Chris Bergen have established prearranged trading plans to sell shares of the company's common stock over a designated period. The stock trading plans are part of their personal ongoing long-term strategy for tax planning and asset diversification and were adopted in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934 and Kendle's policy regarding stock transactions by its insiders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

Under the trading plans, during a six-month period commencing March 20, 2008, and ending Sept. 30, 2008, Dr. Kendle and Mr. Bergen plan to sell up to 550,715 and 302,136 shares of KNDL common stock, respectively, in open market transactions. Transactions under this plan will be disclosed publicly by Dr. Kendle and Mr. Bergen through Securities and Exchange Commission filings.

Rule 10b5-1 permits insiders to implement a written plan to sell stock when they are not in possession of material non-public information and continue to sell shares on a regular basis even if they receive such information subsequently. Such plans establish predetermined trading parameters that do not permit the person adopting the plan to exercise any subsequent influence over how, when, or whether to affect trades. Using these plans, insiders can gradually diversify their investment portfolios, spread stock trades out over an extended period of time to reduce market impact, and avoid concerns about transactions occurring at a time when they might possess inside information.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip. Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
2. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
3. Kendle to Present at the Wachovia 2008 Healthcare Conference
4. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
5. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
6. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
7. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
8. Kendle to Present at the UBS Global Life Sciences Conference
9. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
10. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... ... transfer solution that makes it easy for organizations to send and gather large ... cumbersome FTP software or email file size limitations. , Using the same ...
(Date:5/23/2017)... ... May 22, 2017 , ... ... in San Diego, California, this August will feature high-level speakers on quantum ... vehicles. , SPIE Optics and Photonics, the largest multidisciplinary optical sciences meeting in ...
(Date:5/23/2017)... ... ... Cambridge Semantics , the leading provider of Big Data management and analytics ... in Boston May 23-25 with a featured speaker and solution demos of its ... also a finalist for the Best of Show award. , James LaPointe, Managing Director ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... ... meeting and educational conference of the American Association of Bioanalysts (AAB) and the ... Hotel in Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory ...
Breaking Biology Technology:
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):